News Briefs

Express Scripts and Prime Therapeutics LLC unveiled a partnership by which the former will offer the latter services related to retail pharmacy network and drug manufacturer contracts. Through the three-year deal, Express Scripts, a Cigna Corp. subsidiary, will provide pharmacy network development and negotiate with drugmakers for pharmacy benefit drugs on behalf of Prime’s 28 million members, as well as its own 75 million customers. Each company will work independently on managing medical benefit therapies and value-based contracting. In a Jan. 7 Drug Channels blog, Adam Fein, Ph.D., CEO of Drug Channels Institute, a subsidiary of Pembroke Consulting, Inc., maintains that the transaction “has potentially major implications,” as “manufacturers and pharmacies will face the biggest PBM ever.” Contact Prime’s Karen Lyons at klyons@primetherapeutics.com and Cigna’s Will McDowell at William.mcdowell2@cigna.com. Read Fein’s blog at https://bit.ly/36xvnJb.

Prime Therapeutics has entered into an oncology value-based arrangement with Pfizer Inc. “Prime will utilize real-world patient pharmacy data to support a value-based agreement related to patients’ adherence to their cancer treatment,” says that company in a press release. Prime declined to respond to AIS Health questions about the partnership. Contact Prime’s Jenine Anderson at jenine.anderson@primetherapeutics.com.

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-specialty-pharmacy-FDA-Extends-Xeljanz-Safety-Warnings-to-Other-JAK-Inhibitors.jpg
October 14

FDA Extends Xeljanz Safety Warnings to Other JAK Inhibitors

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured_FDA-Requires-Warnings-on-Labels-of-JAK-Inhibitors-for-Inflammatory-Conditions.jpg
October 14

FDA Approves Byooviz, First Ophthalmology Biosimilar in U.S.

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-specialty-pharmacy-Groups-Warn-Against-Avastin-Biosimilar-Off-Label-Use-in-Eyes.jpg
October 14

Groups Warn Against Avastin Biosimilar Off-Label Use in Eyes

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today